Our chief editor explains that the rationale for creating some of our most popular sections was to give readers the insights and perspectives of those who have “been there, experienced that.”
Rob Wright discusses China’s history of intellectual property (IP) theft, and wonders if the government-sponsored 10-year initiative, Made in China 2025 (MIC 2025), could exacerbate the problem.
Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.
This month’s issue, like many before, features a variety of executives who have demonstrated a willingness to take significant risks.
Six months after Amgen acquired Onyx Pharmaceuticals, Tony Coles, M.D. was pondering his next move. The former Onyx CEO wasn’t planning to lead another pharma company so soon … but then he got a phone call.
Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.
A question about GMOs submitted to our editorial board leads us to look more closely into this issue and how it affects the pharma industry.
Amir Kalali, M.D., former global head of Quintiles (now IQVIA) neuroscience center of excellence, provides insight on why he decided to found an educational conference, The CNS Summit, while still working as a biopharmaceutical industry executive.
What current biopharma leaders have the potential to “transcend” beyond this industry? Chief Editor Rob Wright gives his top three choices.